Mesa Labs 1Q24 revenue $50.6M (+0.4%), net loss $(0.10)/share, AOI up 46% to $9.5M

MESA LABORATORIES INC /CO/

2024-Q1 EPS reported -$0.10 revenue$50,645,000

Revenue $50.6M, +0.4% YoY; core organic growth 2.0% (ex-currency/COVID).
Operating loss narrowed 85.5% to $(0.7M); net loss $(0.5M) or $(0.10)/share.
Non-GAAP AOI excluding unusual items rose 46.2% to $9.5M (18.8% of revenue).
Divisions: Calibration +12.5% core organic, Sterilization +7.2%, Clinical Genomics -4.4%, Biopharma -6.6%.
Headwinds: slowing capital equipment, Sema4 loss, currency; cost cuts aiding profitability.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MESA LABORATORIES INC /CO/ reported the three months ended June 30, 2023 results: revenue $50,645, net income $(549), EPS $(0.10) per diluted share.

Period: the three months ended June 30, 2023
Revenue: $50,645
Net income: $(549)
EPS: $(0.10) per diluted share
Result: reported results

Exact text from the filing

Total revenues were $50,645, an increase of 0.4% compared to the first quarter of fiscal year 2023 (“1Q23”) as last year’s acquisition of Belyntic made a modest contribution to revenue. Operating loss decreased 85.5% to $ (664). Net loss was $(549), a decrease of 61.8% or $(0.10) per diluted share of common stock.

View on SEC.gov

Browse all earnings releases →

MESA LABORATORIES INC /CO/ filing history →

Source: SEC EDGAR

accession 0001437749-23-021752

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.